Pathophysiological Basis

DMD results from out-of-frame mutations in the DMD gene (chromosome Xp21), causing absent dystrophin.
Pathogenesis involves sarcolemmal tearing, massive calcium influx, chronic inflammation, myonecrosis, and fibrofatty replacement.
DMTs aim to restore dystrophin expression, bypass premature termination codons, or suppress downstream inflammation and fibrosis.

Standard Baseline DMT: Corticosteroids and Innovations

Standard Corticosteroids: Foundational DMT for all patients.
- Prednisolone: $0.75\text{ mg/kg/day}$ orally.
- Deflazacort: $0.9\text{ mg/kg/day}$ orally.
- Mechanism: Suppresses T-cell/macrophage inflammation, inhibits Nuclear Factor-kappa B (NF-κB), and up-regulates utrophin. Prolongs ambulation by 2–3 years.
- Alternative Dosing: Weekend dosing ($10\text{ mg/kg/week}$ over 2 days) preserves muscle strength with a favorable side-effect profile.
Dissociative Steroids (Vamorolone):
- Engineered to retain potent anti-inflammatory transrepression while actively failing to recruit co-activators for transactivation (which drives classic steroid toxicity).
- Reduces risks of stunted growth, osteoporosis, and behavioral outbursts.
- Recommended starting dose is $6\text{ mg/kg/day}$.

Utilizes synthetic RNA analogs to bind target exons during pre-mRNA splicing, forcing the machinery to "skip" mutated segments.
Restores the reading frame, converting the severe DMD phenotype into a milder Becker Muscular Dystrophy (BMD) phenotype with truncated dystrophin.
Next-Generation ASOs: Agents like del-zota (exon 44) and z-rostudirsen (exon 51) are conjugated to Transferrin Receptor 1 (TfR1) monoclonal antibodies, delivering tenfold higher dystrophin expression.

Ataluren: Indicated strictly for nonsense mutations (premature stop codons: UAA, UAG, UGA), representing 10–15% of cases.
Interacts with ribosomes to bypass the premature termination codon, allowing synthesis of full-length dystrophin. Administered orally three times daily.

Delandistrogene Moxeparvovec (Elevidys): One-time recombinant gene therapy using an Adeno-Associated Virus Serotype rh74 (AAVrh74) vector.
Delivers a highly truncated "micro-dystrophin" transgene retaining essential actin-binding and cysteine-rich domains, driven by a muscle-specific promoter (MHCK7).
Remains episomal in post-mitotic motor neurons without integrating into the host genome.
Safety and 2025 FDA Mandates:
- Risk of fatal acute liver failure and immune-mediated myositis driven by massive cytotoxic T-cell responses.
- Restricted strictly to ambulatory patients $\ge$ 4 years old.
- Requires extreme peri-infusion immunosuppression (Sirolimus plus high-dose corticosteroids).

Givinostat (Duvyzat): Oral non-steroidal Histone Deacetylase (HDAC) inhibitor.
Halts pathological epigenetic signaling, drastically suppressing pro-inflammatory cytokines and fibrofatty scar tissue deposition.
Approved for $\ge$ 6 years; requires rigorous monitoring for thrombocytopenia, hypertriglyceridemia, and QTc prolongation.

Drug Class	Modality / Agent	Genetic Indication	Key Mechanism
Corticosteroids	Prednisolone, Deflazacort	All mutations	Inhibits NF-κB, reduces inflammation
Dissociative Steroid	Vamorolone	All mutations	Transrepression without transactivation
ASO Exon 51	Eteplirsen	Exon 51 skipping (13% of cases)	Restores reading frame
ASO Exon 53	Golodirsen, Viltolarsen	Exon 53 skipping (8–10% of cases)	Restores reading frame
ASO Exon 45	Casimersen	Exon 45 skipping (~8% of cases)	Restores reading frame
Read-Through	Ataluren	Nonsense mutations (10–15% of cases)	Ribosomal bypass of stop codons
Micro-Dystrophin	Delandistrogene moxeparvovec	Confirmed DMD mutation	AAVrh74 delivery of engineered transgene
HDAC Inhibitor	Givinostat	All mutations	Epigenetic modulation of fibrosis

Duchenne Muscular Dystrophy is a severe X-linked recessive disorder caused by out-of-frame mutations in the DMD gene on chromosome Xp21.
Complete absence of functional dystrophin results in severe sarcolemmal fragility, massive calcium influx, chronic inflammation, and progressive fibro-fatty muscle replacement.
Disease-modifying therapies aim to restore dystrophin expression, bypass premature termination codons, or suppress downstream inflammatory cascades to prolong independent ambulation.

Traditional glucocorticoids (Prednisolone at 0.75 mg/kg/day or Deflazacort at 0.9 mg/kg/day) remain the foundational standard of care to suppress T-cell and macrophage-mediated inflammation.
Vamorolone is a first-in-class dissociative steroid that retains potent anti-inflammatory effects but actively minimizes typical steroid toxicities, drastically reducing the risk of stunted growth and bone demineralization.

Antisense oligonucleotides are synthetic RNA analogs designed to mask specific exons during pre-mRNA splicing.
This restores the translational reading frame, converting the severe phenotype into a milder Becker-like phenotype by synthesizing partially functional, truncated dystrophin.

Drug Target	Approved Agents	Clinical Notes
Exon 51	Eteplirsen, z-rostudirsen	Applicable to roughly 13% of patients. Next-generation therapies like z-rostudirsen utilize TfR1-targeted delivery for increased expression.
Exon 53	Golodirsen, Viltolarsen	Applicable to 8-10% of patients with specific deletions.
Exon 45	Casimersen	Applicable to approximately 8% of the patient population.
Exon 44	del-zota	Next-generation therapy conjugated to a Transferrin Receptor 1 monoclonal antibody.

Delandistrogene moxeparvovec-rokl utilizes a non-replicating Adeno-Associated Virus Serotype rh74 vector to deliver a highly truncated micro-dystrophin transgene driven by a muscle-specific promoter.
Indicated strictly for ambulatory patients aged 4 years and older.
Carries severe boxed warnings for rapid serious liver injury and immune-mediated toxicities, mandating extreme peri-infusion immunosuppression.

Ataluren: Nonsense mutation read-through therapy enabling ribosomes to bypass premature stop codons to synthesize full-length dystrophin.
Givinostat: A potent oral Histone Deacetylase inhibitor that down-regulates pro-inflammatory cytokines and heavily blocks fibrofatty substitution, altering global gene transcription.